Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) will likely be posting its Q4 2024 quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Spyre Therapeutics to post earnings of ($0.89) per share and revenue of $2.10 million for the quarter.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Spyre Therapeutics Trading Up 7.2 %

Shares of SYRE stock traded up $1.33 on Friday, hitting $19.70. 651,522 shares of the stock were exchanged, compared to its average volume of 601,152. Spyre Therapeutics has a fifty-two week low of $18.26 and a fifty-two week high of $47.97. The business has a 50-day moving average of $22.36 and a 200 day moving average of $26.81. The firm has a market capitalization of $1.01 billion, a P/E ratio of -2.64 and a beta of 2.85.

Analyst Ratings Changes

A number of research firms recently weighed in on SYRE. Wedbush reaffirmed an "outperform" rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Robert W. Baird upped their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $54.83.

Remove Ads

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).